The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 11, 2025

Filed:

Jun. 17, 2024
Applicant:

Arcutis Biotherapeutics, Inc., Westlake Village, CA (US);

Inventor:

David Osborne, Fort Collins, CO (US);

Assignee:

ARCUTIS BIOTHERAPEUTICS, INC., Westlake Village, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/44 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/14 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); C09K 15/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/44 (2013.01); A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/145 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); C09K 15/06 (2013.01);
Abstract

An improved method is provided for treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.


Find Patent Forward Citations

Loading…